| Article ID | Journal | Published Year | Pages | File Type |
|---|---|---|---|---|
| 10919457 | Radiotherapy and Oncology | 2012 | 4 Pages |
Abstract
Tolerability to gemcitabine radiochemotherapy was evaluated in 33 patients with inoperable, locally advanced transitional-cell bladder cancers. The dose of 75Â mg/m2 gemcitabine once a week, concurrently with standard radiotherapy of 60Â Gy/6Â weeks, was found to be acceptable. Eighty-one percentage of 3-year local progression-free survival suggests efficiency warranting further studies.
Related Topics
Life Sciences
Biochemistry, Genetics and Molecular Biology
Cancer Research
Authors
Kragelj Borut, Zaletel-Kragelj Lijana,